An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) concurrent with Cisplatin and Radiotherapy in histologically Documented Squamous Cell Carcinoma of the Cervix.

Trial Profile

An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) concurrent with Cisplatin and Radiotherapy in histologically Documented Squamous Cell Carcinoma of the Cervix.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Status changed from recruiting to active, no longer recruiting as per the results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results (n=74) assessing safety and efficacy at the end of 2 year presented at the 42nd European Society for Medical Oncology Congress
    • 08 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top